{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=6", "query": { "condition": "Urinary Bladder Neoplasm", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 939, "total_pages": 94, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urinary+Bladder+Neoplasm&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T06:54:14.483Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04561362", "title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Bladder Neoplasm", "Triple Negative Breast Neoplasms", "Hormone Receptor Positive, HER2-negative Neoplasms", "Hormone Receptor Positive, HER2-low Neoplasms", "Breast Neoplasms", "Non-Small-Cell Lung Neoplasms", "Ovarian Neoplasm", "Advanced Solid Tumor" ], "interventions": [ { "name": "BT8009", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BicycleTx Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-07-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 9, "location_summary": "Denver, Colorado • Ocala, Florida • Orlando, Florida + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04561362" }, { "nct_id": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Myelosuppression Adult", "Chemotherapy-induced Neutropenia", "Metastatic Bladder Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-06-04", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 13, "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887831" }, { "nct_id": "NCT03532451", "title": "Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nivolumab/Lirilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PrECOG, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-03-22", "completion_date": "2022-10-05", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 8, "location_summary": "Tampa, Florida • New York, New York • The Bronx, New York + 5 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532451" }, { "nct_id": "NCT00005086", "title": "Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "1999-08", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 4, "location_summary": "Chicago, Illinois • Peoria, Illinois • Fort Wayne, Indiana", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005086" }, { "nct_id": "NCT05363605", "title": "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Head and Neck Squamous Cell Carcinoma", "Bladder Carcinoma", "Susceptible FGFR3 Genetic Alterations", "FGFR3", "FGFR3 Overexpression", "FGFR3 Receptor", "FGFR3 Protein Overexpression", "Ovarian Cancer", "Colorectal Cancer", "Breast Cancer", "Liver Cancer", "Lung Cancer", "Gastric Cancer" ], "interventions": [ { "name": "[225Ac]-FPI-1966", "type": "DRUG" }, { "name": "[111In]-FPI-1967", "type": "DRUG" }, { "name": "vofatamab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fusion Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-04-20", "completion_date": "2023-09-08", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 4, "location_summary": "Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05363605" }, { "nct_id": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2022-05-03", "completion_date": "2029-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 158, "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Arcadia", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879329" }, { "nct_id": "NCT06337305", "title": "Resiliency in Patients Undergoing Radical Cystectomy for Bladder Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bladder Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2020-08-19", "completion_date": "2023-08-19", "has_results": false, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06337305" }, { "nct_id": "NCT07097142", "title": "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Muscle Invasive Bladder Urothelial Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Ultrahypofractionated Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 486, "start_date": "2025-10-07", "completion_date": "2035-05-31", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 258, "location_summary": "Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07097142" }, { "nct_id": "NCT01611662", "title": "Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Distal Urethral Cancer", "Proximal Urethral Cancer", "Squamous Cell Carcinoma of the Bladder", "Stage II Bladder Cancer", "Stage III Bladder Cancer", "Urethral Cancer Associated With Invasive Bladder Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2012-05-29", "completion_date": "2019-01-22", "has_results": true, "last_update_posted_date": "2019-07-29", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01611662" }, { "nct_id": "NCT04916990", "title": "Improving Care for Rural Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer", "Head and Neck Cancer", "Thyroid Cancer", "Cervical Cancer", "Breast Cancer", "Bladder Cancer", "Colon Cancer", "Rectum Cancer" ], "interventions": [ { "name": "CARES Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 320, "start_date": "2022-09-01", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-29T06:54:14.483Z", "location_count": 14, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04916990" } ] }